[1] Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet, 2015, 386: 1546-1555.
[2] Yuen MF, Wong DE, Tse E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects. Hepatology, 2004, 39: 1694-1701.
[3] Bréchot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely “occult”. Hepatology, 2001, 34: 194-203.
[4] Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology, 2006, 131: 59-68.
[5] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut, 2015, 64: 1972-1984.
[6] Boyd A, Lacombe K, Lavocat F, et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol, 2016, 65: 683-691.
[7] Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy 1. Gastroenterology, 2004, 126: 1750-1758.
[8] Amaddeo G, Cao Q, Ladeiro Y, et al. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut, 2015, 64: 820-829.
[9] Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology, 2010, 139: 474-482.
[10] Wang H, Fang M, Gu X, et al. The intracellular HBV DNAs as novel and sensitive biomarkers for the clinical diagnosis of occult HBV infection in HBeAg negative hepatocellular carcinoma in China. PloS One, 2014, 9: e107162.
[11] Bai F, Yoshihiko Y, Takumi F, et al. Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma. Int J Hepatol, 2013, 2013:1-9.
[12] Wang Q, Fiel MI, Luan W, et al. Impact of intrahepatic hepatitis B DNA and covalently closed circular DNA on survival after hepatectomy in HBV-associated hepatocellular carcinoma patients. Ann Surg Oncol, 2013, 20: 3761-3770.
[13] Bertoletti A, Tan AT, Gehring AJ. HBV-specific adaptive immunity. Viruses, 2009, 1: 91-103.
[14] Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med, 1996, 2: 1104-1108.
[15] Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science, 2014, 343: 1221-1228.
[16] Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments.. JAMA, 2015, 313: 1617-1618.
[17] Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med, 2001, 344: 68-69.
[18] Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol,2014, 32: 3736-3743.
[19] Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis. Hepatology, 2003, 38: 86-95.
[20] Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol, 2007, 45: 3942-3947.
[21] Park Y, Hong DJ, Shin S, et al. Performance evaluation of new automated hepatitis B viral markers in the clinical laboratory two auantitative hepatitis B surface antigen assays and an HBV core-related antigen assay. Am J Clin, 2012, 137: 770-775.
[22] Kimura T, Ohno N, Terada N, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem, 2005, 280: 21713-21719.
[23] Luckenbaugh L, Kitrinos KM, Delaney WE Hu J, et al. Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy. J Viral Hepat, 2015, 22: 561-570.
[24] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut, 2015, 64: 1972-1984.
[25] Königer C, Wingert I, Marsmann M, et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci USA, 2014, 111: 4244-4253.
[26] Kennedy EM, Kornepati AV, Cullen BR. Targeting hepatitis B virus cccDNA using CRISPR/Cas9. Antiviral Res, 2015, 123:188-192.
[27] Zeisel MB, Lucifora J, Mason WS, et al. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure.. Gut, 2015, 64: 1314-1326. |
